Practical guidance for the management of adults with immune thrombocytopenia during the COVID‐19 pandemic

2020/05/06 by Sue Pavord, Jecko Thachil, Thachil Jecko +10 · 25 citations
Medicine · #Platelet Disorders and Treatments #Blood properties and coagulation #Blood groups and transfusion

paper · doi:10.1111/bjh.16775

Abstract

This document aims to provide practical guidance for the assessment and management of patients with thrombocytopenia, with a particular focus on immune thrombocytopenia (ITP), during the COVID-19 pandemic. The intention is to support clinicians and, although recommendations have been provided, it is not a formal guideline. Nor is there sufficient evidence base to conclude that alternative approaches to treatment are incorrect. Instead, it is a consensus written by clinicians with an interest in ITP or coagulation disorders and reviewed by members of the UK ITP forum.

Citations

• Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (<scp>ITP</scp>) for up to 1 year and in those with chronic <scp>ITP</scp> for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies

Cited by

• Thrombocytopenia is independently associated with poor outcome in patients hospitalized for COVID-19. [europepmc]
• Oral erosions and petechiae during SARS-CoV-2 infection. [europepmc]
• Immune thrombocytopenia in a patient with COVID-19. [europepmc]
• Clinical characteristics, management and outcome of COVID-19-associated immune thrombocytopenia: a French multicentre series. [europepmc]
• COVID-19 patient with immune thrombocytopenic purpura. [europepmc]
• Immune thrombocytopenic purpura after COVID-19 infection. [europepmc]
• Immune Thrombocytopenia Secondary to COVID-19: a Systematic Review. [europepmc]
• Telemedicine in patients with haematological diseases during the coronavirus disease 2019 (COVID-19) pandemic: selection criteria and patients' satisfaction. [europepmc]
• Primary Immune Thrombocytopenia: Novel Insights into Pathophysiology and Disease Management. [europepmc]
• Outcomes and management of immune thrombocytopenia secondary to COVID-19: Cleveland clinic experience. [europepmc]
• Severe, Refractory Immune Thrombocytopenia Occurring After SARS-CoV-2 Vaccine. [europepmc]
• Incidence, characteristics and clinical profile of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with pre-existing primary immune thrombocytopenia (ITP) in Spain. [europepmc]
• Practical Recommendations for the Management of Patients with ITP During the COVID-19 Pandemic. [europepmc]
• Platelets in the perspective of COVID-19; pathophysiology of thrombocytopenia and its implication as prognostic and therapeutic opportunity. [europepmc]
• A real-world study of immune thrombocytopenia management during the COVID-19 pandemic in the UK. [europepmc]
• Philadelphia-Negative Chronic Myeloproliferative Neoplasms during the COVID-19 Pandemic: Challenges and Future Scenarios. [europepmc]
• Of vascular defense, hemostasis, cancer, and platelet biology: an evolutionary perspective. [europepmc]
• COVID-19 associated with immune thrombocytopenia: a systematic review and meta-analysis. [europepmc]
• Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives. [europepmc]
• Real-world, single-center experience of SARS-CoV-2 vaccination in immune thrombocytopenia. [europepmc]
• Pulmonary embolism in a patient with eltrombopag-treated aplastic anaemia and paroxysmal nocturnal haemoglobinuria clone during COVID-19 pneumonia. [europepmc]
• How we treat primary immune thrombocytopenia in adults. [europepmc]
• Use of thrombopoietin receptor agonists in adults with immune thrombocytopenia: a systematic review and Central European expert consensus. [europepmc]
• Knowledge mapping of immune thrombocytopenia: a bibliometric study. [europepmc]
• Recommendations for the Clinical Approach to Immune Thrombocytopenia: Spanish ITP Working Group (GEPTI). [europepmc]

Related

• Systematic literature review of treatments used for adult immune thrombocytopenia in the second‐line setting
• Risk‐based and individualised management of bleeding and thrombotic events in adults with primary immune thrombocytopenia (<scp>ITP</scp>)
• A British Society for Haematology Guideline: Diagnosis and management of thrombotic thrombocytopenic purpura and thrombotic microangiopathies
• Avatrombopag in adults with immune thrombocytopenia: A multicentre real‐life observational study in Madrid, Spain (<scp>AVAMAD</scp> study)
• Real‐world evidence of avatrombopag for the treatment of immune thrombocytopenia intolerant or ineffective to eltrombopag/hetrombopag